Origin & tradition
NMN is not a traditional remedy but a modern molecule at the center of the NAD+ longevity field studied at Harvard and Washington University. NAD+, the coenzyme it feeds, declines with age.
Western tradition · NAD+ precursor · Longevity supplement
The headline NAD+ booster of the longevity world — human trials show it raises blood NAD+ and may support physical function.
Data definition. Matched records include all indexed medical endpoints for this intervention — not only longevity. Longevity-relevant records are screened separately and cited in the evidence summary below. Counts are matched-record volumes, not de-duplicated trials and not efficacy claims.
NMN is not a traditional remedy but a modern molecule at the center of the NAD+ longevity field studied at Harvard and Washington University. NAD+, the coenzyme it feeds, declines with age.
Key active: Nicotinamide mononucleotide (NAD+ precursor).
NMN is a direct precursor to NAD+, the coenzyme that fuels mitochondrial energy and sirtuin activity and declines with age. A 2022 randomized, placebo-controlled trial in healthy middle-aged adults found dose-dependent increases in blood NAD+ and improved six-minute walking distance.
Effect summary
| Health outcome | Effect | Magnitude | Grade |
|---|---|---|---|
| NAD+ blood levels | Increases | Strong | B |
| Physical endurance / VO2 max | Increases | Minor | C |
| Insulin sensitivity | Increases | Minor | C |
| DNA repair markers | Increases | Minor | C |
| Skin hydration & elasticity | Increases | Minor | C |
| Blood pressure | No change | Negligible | D |
Grade: A = robust RCTs · B = several RCTs / meta-analysis · C = limited or mixed RCTs · D = observational or early data
Dosage guidance
Higher doses up to 1,500 mg/day studied in some trials; start low. Sublingual may improve absorption.
Informational only — not a prescription or personalised medical advice. Consult a qualified clinician before starting any supplement or medication.
Evidence summary
Human RCTs on NAD+ levels & physical function; long-term longevity outcomes still open
NMN is a direct precursor to NAD+, the coenzyme that fuels mitochondrial energy and sirtuin activity and declines with age. A 2022 randomized, placebo-controlled trial in healthy middle-aged adults found dose-dependent increases in blood NAD+ and improved six-minute walking distance.
According to PubMed and ClinicalTrials.gov: trial counts from ClinicalTrials.gov, peer-reviewed literature from PubMed. Counts auto-refresh weekly; last checked 2026-07-19. They include trials across many endpoints, not only longevity.
Informational only — not medical advice, a treatment claim, or a substitute for a qualified clinician. Evidence strength varies; we show mixed and null results on purpose.
Evidence collections
Compare the evidence
The leading NMN alternative — a direct NAD+ precursor with multiple RCTs confirming it safely raises NAD+ levels in humans.
The simplest and cheapest NAD+ precursor — with extensive human trial data in skin aging and DNA repair.
A flavone from parsley and chamomile that inhibits CD38 (NADase) — preserving NAD+ through a complementary mechanism to NMN or NR.
A more bioavailable cousin of resveratrol, often paired with NAD precursors in longevity formulas.
Compare the evidence
Suppliers
Tell us what you need and we will source suppliers for you.